SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-008864
Filing Date
2023-02-27
Accepted
2023-02-27 16:06:08
Documents
14
Period of Report
2023-02-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10048935_8k.htm   iXBRL 8-K 28645
2 EXHIBIT 99.1 brhc10048935_ex99-1.htm EX-99.1 19375
6 image00003.jpg GRAPHIC 3437
  Complete submission text file 0001140361-23-008864.txt   196431

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pdsb-20230227.xsd EX-101.SCH 3871
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pdsb-20230227_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pdsb-20230227_pre.xml EX-101.PRE 16048
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10048935_8k_htm.xml XML 4239
Mailing Address 25B VREELAND ROAD SUITE 300 FLORHAM PARK NJ 07932
Business Address 25B VREELAND ROAD SUITE 300 FLORHAM PARK NJ 07932 800-208-3343
PDS Biotechnology Corp (Filer) CIK: 0001472091 (see all company filings)

IRS No.: 264231384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37568 | Film No.: 23674751
SIC: 2834 Pharmaceutical Preparations